THEMIS2 and cancer: To test whether CPT could affect THEMIS2 expression and cancer stemness, we treated MDA-MB-231 cells with a relatively low and noncytotoxic dose of CPT (20 μM) and compared the resulting gene expression profile with that of the untreated control cells through RNA-sequencing and GO enrichment analysis.